Efficacy of Cisapride in Functional Dyspepsia Resistant to Domperidone or Metoclopramide: A Double-Blind, Placebo-Controlled Study: General Discussion

A randomized, double-blind, placebo-controlled study was conducted to evaluate the efficacy of GutGard, an extract ofGlycyrrhiza glabra, in patients with functional dyspepsia. The primary outcome variables of the study were the change in the severity symptoms and the global assessment of efficacy. The quality of life was evaluated as a secondary outcome measure. The patients received either placebo or GutGard (75 mg twice daily) for 30 days. Efficacy was evaluated in terms of change in the severity of symptoms (as measured by 7-point Likert scale), the global assessment of efficacy, and the assessment of quality of life using the short-form Nepean Dyspepsia Index. In comparison with placebo, GutGard showed a significant decrease (P≤.05) in total symptom scores on day 15 and day 30, respectively. Similarly, GutGard showed marked improvement in the global assessment of efficacy in comparison to the placebo. The GutGard group also showed a significant decrease (P≤.05) in the Nepean dyspepsia index on day 15 and 30, respectively, when compared to placebo. GutGard was generally found to be safe and well-tolerated by all patients. GutGard has shown significant efficacy in the management of functional dyspepsia.

Download Full-text

Correction to: A double-blind placebo controlled study of acotiamide hydrochloride for efficacy on gastrointestinal motility of patients with functional dyspepsia

Journal of Gastroenterology ◽

10.1007/s00535-020-01758-9 ◽

2021 ◽

Vol 56 (2) ◽

pp. 191-191

Author(s):

Kumiko Nakamura ◽

Toshihiko Tomita ◽

Tadayuki Oshima ◽

Haruki Asano ◽

Takahisa Yamasaki ◽

...

Keyword(s):

Functional Dyspepsia ◽

Gastrointestinal Motility ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Efficacy and Safety of the Cudrania tricuspidata Extract on Functional Dyspepsia: A Randomized Double-Blind Placebo-Controlled Multicenter Study

Journal of Clinical Medicine ◽

10.3390/jcm10225323 ◽

2021 ◽

Vol 10 (22) ◽

pp. 5323

Author(s):

Jinyoung Shin ◽

Tae-Hoon Oh ◽

Joo-Yun Kim ◽

Jae-Jung Shim ◽

Jung-Lyoul Lee

Keyword(s):

Functional Dyspepsia ◽

Rating Scale ◽

Gastrointestinal Symptoms ◽

Controlled Study ◽

Caffeine Intake ◽

Control Group ◽

Double Blind ◽

Cudrania Tricuspidata ◽

Double Blind Placebo ◽

Folk Remedy

Cudrania tricuspidata is a folk remedy used to treat inflammation in patients with tumors or liver damage. This study investigated the efficacy of Cudrania tricuspidata extract (CTE) for relieving the symptoms of functional dyspepsia. In an 8-week, randomized, double-blind, placebo-controlled study, 100 adults with any condition featured in the Rome IV criteria and a Gastrointestinal Symptoms Scale (GIS) score ≥4 were randomly allocated to take either a placebo (maltodextrin) or a 50 mg CTE tablet, which equally included celluloses, magnesium stearate, and silicon dioxide, twice daily, 20 January 2020, and 3 August 2020. Among the 83 participants finally analyzed, the CTE group was associated with a significant reduction in the gastrointestinal symptom rating scale (day 0: 8.0 ± 5.2, day 28: 4.7 ± 3.9, and day 56: 2.3 ± 2.4, p < 0.001, respectively) in comparison with the control group (day 0: 8.1 ± 4.7, day 28: 7.8 ± 5.7, and day 56: 7.5 ± 6.6, p > 0.05) after adjusting for smoking, drinking, eating habits, stress levels, and caffeine intake. The CTE group resulted in significant improvements of GIS, Nepean Dyspepsia Index (Korean version), and functional dyspepsia-related quality of life over time. There were no different adverse events (p = 0.523). These findings suggest that CTE is safe and efficacious for alleviating gastrointestinal symptoms in patients with functional dyspepsia.

Download Full-text